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Introduction
We present a case of a recurrent skull base meningioma
after resection and salvage radiation therapy that highlights
dose considerations and a unique pattern of recurrence,
underscoring the importance of understanding regions at
risk for recurrence during initial treatment planning.
Case presentation
A 55-year-old, otherwise healthy, right-handed man
presented with a 3-month history of declining visual
acuity in the left eye and bifrontal morning headaches.
Visual acuity in the left eye measured 20/150 but the right
eye was preserved at 20/20. A magnetic resonance
imagining (MRI) head scan revealed an extra-axial
mass with an extension into the posterior left orbit and
suspected involvement of the left cavernous sinus,
superior orbital fissure, and optic nerve (Fig 1A,B).
The patient underwent a left pterional craniotomy with
tumor resection and decompression of the optic nerve.
Postoperative pathology revealed a World Health Orga-
nization grade 1 (benign) meningioma with low mitotic
activity and Ki-67 and no necrosis or anaplastic features.
A postoperative MRI scan revealed subtotal resection
(Simpson grade 4) with residual tumor adjacent to the left
cavernous sinus, measuring 4 mm by 10 mm (transverse
by craniocaudal; Fig 1C). Visual acuity in the left eye
improved to 20/25, and the right eye remained at 20/20.
Given the low tumor grade, adjuvant treatment was de-
ferred in favor of annual surveillance imaging.
First recurrence
The patient was asymptomatic with stable imaging
until the fourth-year surveillance MRI scan, which
revealed growth of the residual tumor to 12 mm by
18 mm (Fig 2). Gamma Knife radiation surgery was
contraindicated because of the proximity to the optic
nerve. Subsequently, the patient was considered for
fractionated radiation therapy. The patient had become
symptomatic with diplopia on upward gaze and sensi-
tivity to light. Salvage radiation therapy was delivered to
a dose of 50.4 Gy (1.8 Gy/fraction) via intensity
modulated radiation therapy (IMRT) with a thermo-
plastic mask for immobilization.
Computed tomography (CT) simulation images were
fused with diagnostic MRI images to help with delinea-
tion. The macroscopic tumor on the fused CT and MRI
images of the tumor recurrence was contoured as the
gross tumor volume (GTV) with 1 cm added as a clinical
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target volume (CTV) margin and 0.5 cm added as a
planning target volume margin. The preoperative MRI
scan from the original surgery was used to aid in delin-
eating the recurrent tumor in relation to the original tumor
volume. Daily image guidance included a combination of
cone beam CT and orthogonal electronic portal imaging.
After treatment, there was clinical improvement with
a partial resolution of gaze-dependent diplopia but with
new deficits including left-sided tinnitus and left facial
numbness in the V1 and V2 distributions.
Second recurrence
Surveillance MRI scans taken 8 months after radiation
therapy revealed a slight reduction in tumor size. At 20
months, MRI scans showed stability. Six months before
the next annual surveillance MRI scan, the patient pre-
sented with left facial pain in the V1 and V2 distributions.
Development of trigeminal nerve injury was suspected,
and pain control was initiated with a combination of
carbamazepine, dexamethasone, and hydromorphone.
A contrast-enhanced CT scan revealed no change in the
residual lesion.
The next regularly scheduled surveillance MRI scan
3 months later revealed tumor enlargement with exten-
sions along the floor of the middle cranial fossa and
through the foramen ovale and foramen rotundum into the
infratemporal fossa (Fig 3). The MRI scan that demon-
strated recurrence was fused with the previous treatment
plan, which revealed that the GTV was flush against the
inner table of the skull base with the regrowth of tumor
occurring both within and outside of the previous high-
dose volumes (Fig 4). It was unclear whether these find-
ings indicated radiation-resistant tumor or incomplete
coverage of microscopic disease through the foramina at
the skull base that was unrecognized in the original
treatment plan.
Two neurosurgical opinions were in consensus that a
meaningful surgical decompression was not feasible.
Figure 1 Initial presentation. T1-weighted enhanced magnetic resonance imaging head scans. (A and B) Preoperative. (C) Postoperative.
The green arrows indicate preoperative gross tumor and the red arrow indicates postoperative gross residual disease.
Figure 2 First recurrence after surgical resection. T1-weighted magnetic resonance imaging head scans post-gadolinium. (A) Coronal
view. (B) Axial view. Green arrow indicates gross recurrent tumor.
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Because of the patient’s progressive symptoms, repeat
image guided IMRT to a dose of 54 Gy in 1.8 Gy/fraction
was offered (Fig 5). With an anticipated cumulative dose
greater than 100 Gy to the left cavernous sinus and pos-
terior orbit, the patient was counseled regarding the risk of
visual pathway injury, cranial nerve or brain injury, and
hearing loss. The patient consented to retreatment. Plan-
ning details were similar to those of the first course of
radiation therapy.
At the initial 8-week follow-up visit, improvement was
noted in the patient’s left-sided facial numbness and pain
and a significant reduction in tumor size was found on
MRI scan (Fig 6A). He could be weaned from dexa-
methasone and later discontinued hydromorphone and
tegretol.
Unfortunately, at 6 months, the patient’s trigeminal
paindconsistent with a cranial nerve injurydreturned,
along with a significant decline in left visual acuity
from 20/60 to detecting hand motions only. Opioid
analgesics were reinstituted for pain control. Repeat
imaging scans, however, demonstrated ongoing stability
of the tumor with new enhancements in the medial tem-
poral lobe consistent with radiation injury (Fig 6B). Given
that radiation-related neuropathy is typically painless,
there remained a concern for early tumor recurrence in the
cavernous sinus that was not yet detected on
serial imaging scans. Ongoing clinical and radiologic
monitoring will be required to differentiate between
radiation-induced toxicity and recurrence.
Discussion
We present a case of a skull base meningioma that
recurred after initial surgery and salvage IMRT (50.4
Gy) and was subsequently reirradiated (54 Gy). This
Figure 3 Recurrence after first course of radiation therapy. Coronal T1 weighted magnetic resonance imaging post gadolinium. Green
arrows indicate gross recurrent disease both outside (A) and within (B) the original radiation treatment field.
Figure 4 Recurrent disease after salvage radiation therapy superimposed over the original treatment plan, demonstrating recurrence
outside of the original target volumes. Non-contrast computed tomography images. (A-C) Axial, sagittal, and coronal views, respec-
tively. Green is clinical tumor volume from time of first radiation; magenta is clinical tumor volume per Radiation Therapy Oncology
Group 0539 recommendations; blue is gross tumor volume for recurrent disease after first radiation; and red is 95% isodose line from the
first course of radiation treatment.
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case highlights the issue of dose selection and under-
standing regions at risk for recurrence during treatment
planning.
Meningiomas have a propensity for local infiltration,
and the specific pattern of extension may be indicative
of recurrence rates.1 Regardless, conventional target
volumes typically cover the contrast-enhancing volume
only. For example, typical radiation surgery plans add
no CTV margin,2 and conventionally fractionated
stereotactic plans include minimal or no CTV margin
except in cases of atypical or high-grade tumors in
which subclinical extension is more common.3 In our
case, we speculate that the tumor regrowth after initial
radiation therapy may be attributable to inadequate
target coverage of microscopic disease at the skull base.
In the original plan, the caudal border of the high-dose
volume was flush against the skull base (Fig 4), which
may have excluded microscopic disease that had
Figure 5 Non-contrast computed tomography images. Blue is gross tumor volume for the recurrent tumor. (A-C) Retreatment plan for
recurrence with the 95% isodose line in red. (D-F) Composite plan that sums the doses for the initial and retreatment plans with the
51 Gy (red) and 90 Gy (green) isodose lines indicated.
Figure 6 Post-reirradiation. T1-weighted magnetic resonance imaging head scans post-gadolinium. (A) 8-week follow-up; (B) 6-month
follow-up. Green arrow indicates new enhancement, possibly due to a radiation-related injury.
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extended below the skull base and possibly through the
formina.
Previous reports have also suggested that regional
multicentricity, the presence of microscopic foci of
meningotheliomatous cell aggregates in regional dura,
may also contribute to observed recurrence patterns even
after an apparent complete resection.4 In addition,
meningiomas may evolve over time into more aggressive
variants, which have been associated with inferior salvage
rates with delayed salvage radiation therapy after subtotal
resection.5,6
Initial radiation therapy was limited to 50.4 Gy
because of the proximity of the tumor to the optic nerve.
Despite the lower dose, this was unlikely to be a factor in
the patient’s subsequent recurrence. Previous reports have
demonstrated the effectiveness of 50 to 50.4 Gy in
treating benign meningiomas. A retrospective study
treated 131 patients with benign meningiomas to 50 Gy in
30 to 33 fractions where the tumor involved or was
adjacent to optic structures; the study reported 10-year
local control rates of 100%, 100%, and 89% for tumors
of the optic sheath, cavernous sinus, and skull base,
respectively.7 A prospective observational study of
30 patients with menigiomas that caused visual impair-
ment delivered a mean target dose of 50.4 Gy in 28 frac-
tions, which improved visual symptoms in 40% of cases
and achieved stability in the remainder.8 Of note, the
recently reported Radiation Therapy Oncology Group
(RTOG) 0539 protocol9 recommends a dose of 54 Gy for
recurrent grade 1 tumors with a dose constraint of 50 Gy
for optic nerves. An alternate approach for our case would
have been to deliver a dose of 54 Gy to the original GTV
and accept a lower dose (50 Gy) in regions of overlap
between the target volumes and the optic nerve.
For meningiomas, target volume delineation is
controversial. For example, the inclusion of the entire
dural tail within the prescription dose has been
debated.10 Furthermore, hyperosteotic bone may be
reactive in nature or may harbor infiltrating tumor cells.
In RTOG 0539, recurrent grade 1 and 2 meningiomas
received 54 Gy, with 5-year local control rates of 85%.
Target volumes were defined by the tumor bed on
the postoperative MRI scan, including any nodular
enhancement but excluding cerebral edema and the dural
tail. A CTV margin of 1.0 cm was recommended except
along natural barriers (eg, skull base) where a 0.5 cm
margin was permitted, provided there was no evidence
of bone invasion.9 For reference, an RTOG-style GTV
and CTV are included in Fig 4. This demonstrates that
enhanced coverage supero-laterally would have been
provided, but the inferior border may still have been
undertreated. Fusion of preoperative imaging scans with
planning CT scans at the time of salvage radiation
therapy may be helpful in determining the extent of
contact between the original tumor and fixed structures
such as the base of the skull to better define regions at
risk for recurrence.
Bearing in mind these uncertainties, we recommend
including adjacent foramina at the skull base in target
volumes, which may have been implicitly included in
traditional, nonconformal radiation therapy approaches
but require explicit coverage with modern conformal
techniques. This is likely a worthwhile endeavor for po-
tential reduction in recurrence risk with minimal added
toxicity.
Conclusion
Radiation therapy provides an effective solution to the
anatomical challenges of skull base meningiomas where
complete resection is not possible but treatment planning
requires consideration of areas at risk for recurrence. In
particular, in the postoperative salvage setting, the orig-
inal tumor bed and points of contact along the base of the
skull should be encompassed by target volumes. Suc-
cessful tumor control through reirradiation of recurrent
grade 1 meningioma is possible, albeit with the risk of
radiation-induced toxicity.
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